Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Systemic Sclerosis and Malignancy: A Review of Current Data.

Zeineddine N, Khoury LE, Mosak J.

J Clin Med Res. 2016 Sep;8(9):625-32. doi: 10.14740/jocmr2606w. Review.

2.

Correlation of the clinical parameters with sonographic findings of hemorrhagic cystitis in pediatric hematooncology patients.

Youn IK, Im SA, Lee JW, Chung NG, Cho B.

Springerplus. 2015 Oct 6;4:577. doi: 10.1186/s40064-015-1380-1.

3.

Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis.

Ali R, Baldeo C, Onyenekwe J, Lala R, Landa C, Siddiqi A.

Case Rep Rheumatol. 2015;2015:513602. doi: 10.1155/2015/513602.

4.

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K.

Diabetes Ther. 2015 Sep;6(3):357-75. doi: 10.1007/s13300-015-0128-9.

5.

Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.

Shang W, Ning Y, Xu X, Li M, Guo S, Han M, Zeng R, Ge S, Xu G.

PLoS One. 2015 May 14;10(5):e0126016. doi: 10.1371/journal.pone.0126016.

6.

Pulmonary metastasis in a patient with simultaneous bladder cancer and relapsing granulomatosis with polyangiitis.

Danckers M, Zhou F, Nimeh D, Belmont HM, Steiger DJ.

Am J Case Rep. 2015 May 14;16:287-91. doi: 10.12659/AJCR.893406.

7.

State of the art in the treatment of systemic vasculitides.

Luqmani RA.

Front Immunol. 2014 Oct 13;5:471. doi: 10.3389/fimmu.2014.00471. Review.

8.

Variability of the impact of adverse events on physicians' decision making.

Cozmuta R, Merkel PA, Wahl E, Fraenkel L.

BMC Med Inform Decis Mak. 2014 Sep 25;14:86. doi: 10.1186/1472-6947-14-86.

9.

Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.

Walsh M, Faurschou M, Berden A, Flossmann O, Bajema I, Hoglund P, Smith R, Szpirt W, Westman K, Pusey CD, Jayne DR; European Vasculitis Study Group..

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1571-6. doi: 10.2215/CJN.00100114.

10.

Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1066-73. doi: 10.2215/CJN.08880813.

11.

Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Clain JM, Cartin-Ceba R, Fervenza FC, Specks U.

Ther Adv Musculoskelet Dis. 2014 Apr;6(2):58-74. doi: 10.1177/1759720X13516239. Review.

12.

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M.

Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144.

13.

Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Stankiewicz JM, Kolb H, Karni A, Weiner HL.

Neurotherapeutics. 2013 Jan;10(1):77-88. doi: 10.1007/s13311-012-0172-3. Review.

14.

Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis.

Pepper RJ, Chanouzas D, Tarzi R, Little MA, Casian A, Walsh M, Pusey CD, Harper L, Salama AD; European Vasculitis Study (EUVAS) investigators..

Clin J Am Soc Nephrol. 2013 Feb;8(2):219-24. doi: 10.2215/CJN.03680412. Erratum in: Clin J Am Soc Nephrol. 2013 Apr;8(4):701. Caisian, Alina [corrected to Casian, Alina].

15.

Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T.

Chest. 2012 Nov;142(5):e1S-e111S. doi: 10.1378/chest.12-1044.

16.

Update on diffuse alveolar hemorrhage and pulmonary vasculitis.

Krause ML, Cartin-Ceba R, Specks U, Peikert T.

Immunol Allergy Clin North Am. 2012 Nov;32(4):587-600. doi: 10.1016/j.iac.2012.08.001. Review.

17.

Rituximab for refractory granulomatous eye disease.

Lower EE, Baughman RP, Kaufman AH.

Clin Ophthalmol. 2012;6:1613-8. doi: 10.2147/OPTH.S35521.

18.

Malignancy risk in vasculitis.

Kermani TA, Warrington KJ, Amin S.

Ther Adv Musculoskelet Dis. 2011 Feb;3(1):55-63. doi: 10.1177/1759720X10387460.

19.

Progress in treatment of ANCA-associated vasculitis.

Smith RM, Jones RB, Jayne DR.

Arthritis Res Ther. 2012 Apr 30;14(2):210. doi: 10.1186/ar3797. Review.

20.

Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Lallana EC, Fadul CE.

Curr Neuropharmacol. 2011 Sep;9(3):468-77. doi: 10.2174/157015911796557939.

Items per page

Supplemental Content

Support Center